A later phase 3b trial of the higher 7.2 mg dose, STEP UP, reported mean bodyweight change of 18.7% at 72 weeks versus 15.6% at 2.4 mg and 3.9% with placebo
Recent clinical data shows these medications can produce meaningful metabolic changes across various body weight categories, raising important questions about appropriate patient selection and expected outcomes
Book Appointment Yasmin In Mr Omar was amazing
PT-141 Peptide has been clinically reviewed and considered safe when used with proper guidance, but mild effects can occasionally occur
64% say theyre more mindful with food purchases, and many are budgeting or tracking finances since starting GLP-1s
Women of childbearing potential should discuss pregnancy plans, as semaglutide is contraindicated during pregnancy and should be discontinued at least two months before conception attempts